Navigation Links
SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
Date:3/7/2012

evented body weight gain. These data also support Spherix's other findings that SPX-106T reduced atherosclerotic lesion areas in the aortic arches of LDL receptor-deficient mice fed fructose and glucose.

"As we continue the development program for SPX-106T, we are gaining valuable insight into the therapeutic potential for SPX-106T. We are looking forward to bringing SPX-106T into human clinical trials in 2012," noted Dr. Claire Kruger, CEO of Spherix.

LDL-cholesterol is a known risk factor for the development of atherosclerosis in humans.(4) Spherix has previously shown that LDL-cholesterol is reduced in LDL receptor-deficient mice treated with SPX-106T.

"This is a very exciting time for Spherix," remarked Dr. Robert Lodder, Spherix's President. "We have now tested SPX-106T in two different genetic models and are looking into the underlying mechanisms by which SPX-106T prevents plaque development in the apolipoprotein E-deficient mice. We are also expanding the applications of SPX-106T to other indications where dyslipidemia may be a primary risk factor."

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacture
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
2. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
3. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
4. RainDance Technologies Appoints Olex Vice President, System Development
5. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
6. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
7. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
8. Oncothyreon announces prioritization plan for development programs
9. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
10. New ImmunoSet(TM) ELISA Development Kits
11. New stem cell tools to aid drug development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Five American winners ... Al Maktoum Awards for Medical Sciences", in its 8 ... Arab Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award ... in numerous programs that aim to improve health and ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... on developing diagnostic tests for cancer and other conditions, today ... be presented at the Science for Business BioWin Day 2014, ... . The data come from VolitionRx,s lung cancer pilot ... department of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... developed a device platform that combines electronic components for ... an ultrathin skin-like patch that mounts directly onto the ... temporary tattoo. Led by researcher John A. Rogers, ... University of Illinois, the researchers described their novel skin-mounted ...
... Neb., Aug. 11, 2011 Transgenomic, Inc. (OTC/BB: TBIO) today ... June 30, 2011 and provided a business update. Second ... were $7.7 million, an increase of 50 percent compared with ... was $4.6 million or 59 percent of net sales, compared ...
... Inc. (Nasdaq: GNVC ) today announced that its ... Rights Plan through the adoption of a new Rights Agreement. ... September 7, 2011, which is the date that GenVec,s existing ... was adopted in connection with the expiration of the existing ...
Cached Biology Technology:Smart skin: Electronics that stick and stretch like a temporary tattoo 2Smart skin: Electronics that stick and stretch like a temporary tattoo 3Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... 1:00 p.m. ET) Research published in Nature Chemical Biology ... pathway, termed necroptosis, all target and inhibit RIP1 kinase, ... by trauma such as a heart attack or stroke, ... damage contributing to death or long-term disability. The findings ...
... nuts included in a heart healthy diet reduced low-density ... with qualified health claims, according to researchers. "We looked ... in the health claim for tree nuts, while other ... heart healthy diet," says Dr. Amy E. Griel, a ...
... the mid-1970s, Glenn Shaw of the Geophysical Institute at ... of Arctic haze after collecting aerosol samples from Barrow, ... contain relatively pure air due to its remote locale ... Shaws data indicated there was a murky cloud of ...
Cached Biology News:Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3Macadamia nuts can be included in heart healthy diet 2Atmospheric scientists gear up for collaborative airborne campaigns 2
... the gap between the 500 l and ... the speed of the classic Vivaspin products ... for superior recoveries from very dilute solutions. ... Cellulose Triacetate membranes, Vivaspin 2 offers the ...
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
Goat polyclonal to Lipocalin 2...
... (VMAT2). An antibody made to the C-terminal ... ~55 kDa in postnuclear supernatants of CHO ... type cells (2). Some additional bands, both ... detected and remain unaffected by the inclusion ...
Biology Products: